'Profound' Results With Ibrutinib Add-On in Mantle Cell Lymphoma

Results from the phase 3 SHINE trial show that adding ibrutinib to standard therapy delays progression by 50% in older patients with mantle cell lymphoma.

Related Keywords

Houston ,Texas ,United States ,American ,Michael Wang ,Julier Gralow ,Abbvie Company ,Genentech ,American Society Of Clinical Oncology ,University Of Texas Md Anderson Cancer Center ,Genomic Health ,Novartis ,Astrazeneca ,Janssen Pharmaceuticals ,Cancer Center ,American Society ,Clinical Oncology ,New England Journal ,First Line Use ,Puma Biotechnology ,Mantle Cell Lymphoma ,Hematology ,Lymphoma ,Malignant Lymphoma ,Chemotherapy ,Clinical Research ,Clinical Trials ,Linical Studies ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Multiple Myeloma ,Myeloma ,Plasma Cell Myeloma ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,